HSR26-204: Baseline EORTC QLQ-C30 "Clinically Important" Symptom Burden Predicts Survival and Toxicity in CLL/SLL Across Randomized Ibrutinib Trials.
Saved in:
| Title: | HSR26-204: Baseline EORTC QLQ-C30 "Clinically Important" Symptom Burden Predicts Survival and Toxicity in CLL/SLL Across Randomized Ibrutinib Trials. |
|---|---|
| Authors: | Abuhelwa AY; 1College of Pharmacy, University of Sharjah, Sharjah, UAE; HOA., Almansour SA; 1College of Pharmacy, University of Sharjah, Sharjah, UAE; HOA., Al-Shamsi HO; 2Burjeel Cancer Institute, Burjeel Medical City, Abu Dhabi, UAE.; 3Harvard Medical School, Harvard University, Boston, MA., Abuhelwa Z; 4University of South Florida/H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL., Ziade MA; 5Department of Hematology, Medcare Royal Specialty Hospital, Dubai, UAE., McKinnon RA; 6College of Medicine and Public Health, Flinders University, Bedford Park, South Australia, Australia., Sorich MJ; 6College of Medicine and Public Health, Flinders University, Bedford Park, South Australia, Australia., Hopkins AM; 6College of Medicine and Public Health, Flinders University, Bedford Park, South Australia, Australia. |
| Source: | Journal of the National Comprehensive Cancer Network : JNCCN [J Natl Compr Canc Netw] 2026 Mar 31; Vol. 24 (3.5). Date of Electronic Publication: 2026 Mar 31. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Harborside Press Country of Publication: United States NLM ID: 101162515 Publication Model: Electronic Cited Medium: Internet ISSN: 1540-1413 (Electronic) Linking ISSN: 15401405 NLM ISO Abbreviation: J Natl Compr Canc Netw Subsets: MEDLINE; In Process |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
